Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor
Slim FOURATI,
J Guedj,
Stephane CHEVALIEZ,
THT Nguyen,
F Roudot-Thoraval,
Isaac RUIZ,
Alexandre SOULIER,
G Scoazec,
A Varaut,
Lila POITEAU,
Murielle FRANCOIS,
A Mallat,
Christophe HEZODE,
Jean-Michel PAWLOTSKY,
Aliment Pharmacol Ther. 01/03/2018;47(5) : 665-673 10.1111/apt.14478. 22/12/2017
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage
AH Talal,
EO Dumas,
B Bauer,
RM Rejman,
A Ocque,
GD Morse,
D Lucic,
G Cloherty,
J King,
J Zha,
H Zhang,
DE Cohen,
NS Shulman,
Jean-Michel PAWLOTSKY,
Christophe HEZODE,
J Infect Dis 17/01/2018;217(3) : 474-482 10.1093/infdis/jix495.
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage
AH Talal,
EO Dumas,
B Bauer,
RM Rejman,
A Ocque,
GD Morse,
D Lucic,
G Cloherty,
J King,
J Zha,
H Zhang,
DE Cohen,
NS Shulman,
Jean-Michel PAWLOTSKY,
Christophe HEZODE,
J Infect Dis 17/01/2018;217(3) : 474-482 10.1093/infdis/jix495.
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study
A Brown,
Christophe HEZODE,
E Zuckerman,
GR Foster,
A Zekry,
SK Roberts,
F Lahser,
C Durkan,
C Badshah,
B Zhang,
M Robertson,
J Wahl,
E Barr,
B Haber,
C-SCAPE Study Investigators
J Viral Hepat. 20/11/2017;25(5) : 457-464 10.1111/jvh.12801 14/03/2018
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial).
MP Carrieri,
C Protopopescu,
Z Younossi,
A Vilotitch,
H Fontaine,
V Petrov-Sanchez,
F Marcellin,
F Carrat,
Christophe HEZODE,
M Bourliere,
Patient. 01/10/2017;10(5) : 605-614 10.1007/s40271-017-0232-1.
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
T Asselah,
KV Kowdley,
N Zadeikis,
S Wang,
T Hassanein,
Y Horsmans,
M Colombo,
F Calinas,
H Aguilar,
V De Ledinghen,
PS Mantry,
Christophe HEZODE,
RT Marinho,
K Agarwal,
F Nevens,
M ElKhashab,
J Kort,
R Liu,
TI Ng,
P Krishnan,
CW Lin,
FJ Mensa,
Clin Gastroenterol Hepatol. 22/09/2017;pii: S1542-3565(17) : 31162-X 10.1016/j.cgh.2017.09.027.
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
M Buti,
K Agarwal,
Y Horsmans,
W Sievert,
E Janczewska,
S Zeuzem,
L Nyberg,
RS Jr Brown,
Christophe HEZODE,
M Rizzetto,
R Parana,
S De Meyer,
R De Masi,
D Luo,
K Bertelsen,
J Witek,
Gastroenterology 04/09/2017;146(3) : 744-753.e3 10.1053/j.gastro.2013.11.047. 04/09/2017
Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.
Christophe HEZODE,
M Colombo,
M Bourliere,
U Spengler,
Z Ben-Ari,
SI Strasser,
WM Lee,
L Morgan,
J Qiu,
P Hwang,
M Robertson,
BY Nguyen,
E Barr,
J Wahl,
B Haber,
R Chase,
R Talwani,
VD Marco
Hepatology. 01/09/2017;66(3) : 736-745 10.1002/hep.29139. 20/07/2017
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Christophe HEZODE,
P Lebray,
V De Ledinghen,
F Zoulim,
V Di Martino,
N Boyer,
D Larrey,
D Botta-Fridlund,
C Silvain,
H Fontaine,
L D'Alteroche,
V Leroy,
M Bourliere,
I Hubert-Fouchard,
D Guyader,
I Rosa,
E Nguyen-Khac,
L Fedchuk,
R Akremi,
Y Bennai,
A Filipovics,
Y Zhao,
JP Bronowicki,
Liver Int. 01/09/2017;37(9) : 1314-1324 10.1111/liv.13383 08/03/2017
